April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Hydrus(TM) Aqueous Implant Increases Outflow Facility in Human Anterior Segments
Author Affiliations & Notes
  • Lucinda J. Camras
    Biomedical Engineering, Duke University, Durham, North Carolina
  • Thomas W. Samuelson
    Minnesota Eye Consultants, Minneapolis, Minnesota
    University of Minnesota, Minneapolis, Minnesota
  • Ike K. Ahmed
    Dpt of Ophthalmology & Vision Sciences, University of Toronto, Mississauga, Ontario, Canada
  • Carol B. Toris
    Ophthalmology, Univ of Nebraska Medical Ctr, Omaha, Nebraska
  • Footnotes
    Commercial Relationships  Lucinda J. Camras, Eye Innovations (P), Ivantis (C); Thomas W. Samuelson, Ivantis (C); Ike K. Ahmed, Ivantis (C); Carol B. Toris, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2069. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lucinda J. Camras, Thomas W. Samuelson, Ike K. Ahmed, Carol B. Toris; Hydrus(TM) Aqueous Implant Increases Outflow Facility in Human Anterior Segments. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2069.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effects of the Hydrus(TM) Aqueous Implant (Ivantis, Inc., Irvine CA), a nitinol device that opens the natural outflow pathway through two quadrants of Schlemm’s canal, on outflow facility in a human anterior segment perfusion model.

Methods: : Human eyes were obtained from the National Disease Research Interchange within 48 hours of death. All donors were between 47 and 80 years of age and had no history of ocular disease or surgeries. The anterior segments were isolated and mounted on custom-made fixtures connected to a perfusion system. Baseline outflow facilities of all eyes were calculated from the slope of flow versus pressure by plotting the corresponding flow rates at four perfusion pressure levels (10, 20, 30, and 40 mmHg) assessed over 40 minutes. The Hydrus(TM) device was inserted in the experimental eyes (n = 9) while the control eyes (n = 6) underwent a sham procedure but no device insertion. The outflow facilities of all eyes were measured again. Control eyes and experimental eyes were compared by two-tailed unpaired t-tests. Baseline and second outflow facility measurements from the same eye were compared by two-tailed paired t-test.

Results: : After device implantation in the experimental eyes, the outflow facility increased 95% (p<0.005) from its baseline of 0.24 ± 0.02 to 0.46 ± 0.07 uL/min/mmHg (mean ± SEM, n=9). The second outflow facility measurement of the control eyes did not change significantly from its baseline (0.24 ± 0.03 vs. 0.24 ± 0.04 uL/min/mmHg, n = 6, p = 0.77). There was no significant difference (p = 0.96) between the baseline outflow facility measurements of experimental and control eyes. However after the device was implanted, the experimental eyes had a significantly higher mean outflow facility measurement than the control eyes (p = 0.03).

Conclusions: : The novel Hydrus(TM) Aqueous Implant provides an effective way to increase outflow facility in perfused ex vivo human eye anterior segments.

Keywords: outflow: trabecular meshwork • anterior chamber • anterior segment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.